Cox multivariate analysis
. | P . | HR (95% CI) . |
|---|---|---|
| Survival | ||
| TREC value | .002 | 6.6 (2.0-21.7) |
| Age no more than 25 y | .23 | - |
| CMV R+/D- vs others | .56 | - |
| Disease status | .19 | - |
| Nonmalignant | reference | - |
| Malignant, low risk | .34 | - |
| Malignant, intermediate and high risk | .88 | - |
| F → M | .15 | - |
| ABO compatibility | .02 | 2.7 (1.2-6.2) |
| Bacterial infections | ||
| TREC value | .036 | 2.8 (1.1-7.4) |
| Age no more than 25 y | .87 | - |
| CMV R+/D- vs others | .79 | - |
| Disease status | .66 | - |
| Nonmalignant | reference | - |
| Malignant, low risk | .36 | - |
| Malignant, intermediate and high risk | .39 | - |
| F → M | .23 | - |
| ABO incompatibility | .15 | - |
| CMV infections | ||
| TREC value | .06 | 1.96 (0.97-3.98) |
| Age no more than 25 y | .53 | - |
| CMV R+/D- vs others | .014 | 2.99 (1.21-7.18) |
| Disease status | .47 | |
| Nonmalignant | reference | - |
| Malignant low risk | .40 | - |
| Malignant intermediate and high risk | .23 | - |
| F → M | .5 | - |
| ABO incompatibility | .23 | - |
. | P . | HR (95% CI) . |
|---|---|---|
| Survival | ||
| TREC value | .002 | 6.6 (2.0-21.7) |
| Age no more than 25 y | .23 | - |
| CMV R+/D- vs others | .56 | - |
| Disease status | .19 | - |
| Nonmalignant | reference | - |
| Malignant, low risk | .34 | - |
| Malignant, intermediate and high risk | .88 | - |
| F → M | .15 | - |
| ABO compatibility | .02 | 2.7 (1.2-6.2) |
| Bacterial infections | ||
| TREC value | .036 | 2.8 (1.1-7.4) |
| Age no more than 25 y | .87 | - |
| CMV R+/D- vs others | .79 | - |
| Disease status | .66 | - |
| Nonmalignant | reference | - |
| Malignant, low risk | .36 | - |
| Malignant, intermediate and high risk | .39 | - |
| F → M | .23 | - |
| ABO incompatibility | .15 | - |
| CMV infections | ||
| TREC value | .06 | 1.96 (0.97-3.98) |
| Age no more than 25 y | .53 | - |
| CMV R+/D- vs others | .014 | 2.99 (1.21-7.18) |
| Disease status | .47 | |
| Nonmalignant | reference | - |
| Malignant low risk | .40 | - |
| Malignant intermediate and high risk | .23 | - |
| F → M | .5 | - |
| ABO incompatibility | .23 | - |
HR indicates hazard ratio; 95% CI, 95% confidence interval; R, recipient; D, donor; F → M, female donor into male recipient.
- indicates nonsignificant; HR values were only provided where significant.